The latest update is out from Terns Pharmaceuticals ( ($TERN) ).
Terns Pharmaceuticals has announced the appointment of Heather Turner, a seasoned biotechnology executive, to its Board of Directors as Dr. Ann Taylor steps down after over three years. Turner, with 25 years of experience and a background in strategic, operational, and legal roles, including her recent role as CEO at Carmot Therapeutics, aims to advance Terns’ pipeline in addressing serious diseases like oncology and obesity. Her expertise is expected to bolster Terns’ strategic decisions and drive further growth, focusing on transformative clinical development.
Learn more about TERN stock on TipRanks’ Stock Analysis page.
